Effector Therapeutics
12
1
2
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 100/100
41.7%
5 terminated/withdrawn out of 12 trials
50.0%
-36.6% vs industry average
0%
0 trials in Phase 3/4
40%
2 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML)
Role: collaborator
Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer
Role: collaborator
An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer
Role: lead
Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies
Role: lead
Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART)
Role: lead
Intravenous Zotatifin in Adults With Mild or Moderate COVID-19
Role: lead
Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy
Role: lead
Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of Tomivosertib Combined With Paclitaxel in Advanced Breast Cancer
Role: collaborator
A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral Tomivosertib (eFT-508) in Subjects With Hematological Malignancies
Role: lead
A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors
Role: lead
A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC
Role: lead
A Study to Evaluate eFT508 Alone and in Combination With Avelumab in Subjects With MSS Colorectal Cancer
Role: lead
All 12 trials loaded